Citations

Clear

367 citation(s) found for "Su, Pan".

Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy
Chen, Kexin , Yang, Da , Li, Xiangchun , Sun, Baocun , Song, Fengju , Cao, Wenfeng , Gao, Zhibo, Li, Haixin , Liang, Han , Zhao, Yanrui, Li, Miao , Buckner, Jan C. , Patterson, Scott D. , Reinhard, Christoph , Bhathena, Anahita, Joshi, Deepa, Wang, Yi Michael, Raghavakaimal, Sreekumar, Lü, Xin , Chang, Han , Ba, Sujuan, Luo, Longhai, Cavenee, Webster K. , Zhang, Wei , Hao, Xishan , Chen, Kexin , Buckner, Jan, Sun, Baocun , Brat, Daniel J. , Zheng, Hong , Ye, Xiang , Mischel, Paul S. , Croce, Carlo Maria , Li, Hui , Pan, Yang , Chen, Kexin

Mayo Clinic

Proceedings of the National Academy of Sciences | January 13, 2015 | Volume: 112 | Issue: 4 | Pages: 1107-1112

10.1073/pnas.1422640112 | PMID 25583476 Get It

Significance We have identified a lethal subtype of gastric cancer (GC) that is characterized by high levels of clonal heterogeneity and TP53 (tumor protein P53) mutation. We have also uncovered key novel mutations in the targetable NRG1 (neuregulin-1) and ERBB4 (V-Erb-B2 avian erythroblastic leukemia viral oncogene homolog 4) ligand-receptor pair and identified BRCA2 (breast cancer 2, early onset) mutations as new genetic markers to predict better survival for GC. Our study represents a novel approach for GC personalized medicine and identified novel clinical actionable therapies for GC therapy.
Rationale and design of the Pan African Pulmonary hypertension Cohort (PAPUCO) study: implementing a contemporary registry on pulmonary hypertension in Africa
Thienemann, Friedrich , Dzudié, Anastase , Mocumbi, Ana Olga , Blauwet, Lori A., Sani, Mahmoud U. , Karaye, Kamilu M. , Ogah, Okechukwu S. , Mbanze, Irina, Mbakwem, Amam , Udo, Patience, Tibazarwa, Kemi, Ibrahim, Ahmed S., Burton, Rosie , Stewart, Simon , Blauwet, Lori, Damasceno, Albertino , Sliwa, Karen , Mbakwem, Amam

Mayo Clinic

BMJ Open | October 15, 2014 | Volume: 4 | Issue: 10 | Pages: e005950

10.1136/bmjopen-2014-005950 | PMID 25763797 Get It

Introduction Pulmonary hypertension (PH) is a devastating, progressive disease with increasingly debilitating symptoms and usually shortened overall life expectancy due to a narrowing of the pulmonary vasculature and consecutive right heart failure. Little is known about PH in Africa, but limited reports suggest that PH is more prevalent in Africa compared with developed countries due to the high prevalence of risk factors in the region. Methods and analysis A multinational multicentre registry-type cohort study was established and tailored to resource-constraint settings to describe disease presentation, disease severity and aetiologies of PH, comorbidities, diagnostic and therapeutic management, and the natural course of PH in Africa. PH will be diagnosed by specialist cardiologists using echocardiography (right ventricular systolic pressure >35 mm Hg, absence of pulmonary stenosis and acute right heart failure), usually accompanied by shortness of breath, fatigue, peripheral oedema and other cardiovascular symptoms, ECG and chest X-ray changes in keeping with PH as per guidelines (European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines). Additional investigations such as a CT scan, a ventilation/perfusion scan or right heart catheterisation will be performed at the discretion of the treating physician. Functional tests include a 6 min walk test and the Karnofsky Performance Score. The WHO classification system for PH will be applied to describe the different aetiologies of PH. Several substudies have been implemented within the registry to investigate specific types of PH and their outcome at up to 24 months. Data will be analysed by an independent institution following a data analyse plan. Ethics and dissemination All local ethics committees of the participating centres approved the protocol. The data will be disseminated through peer-reviewed journals at national and international conferences and public events at local care providers.
NT113, a Pan-ERBB Inhibitor with High Brain Penetrance, Inhibits the Growth of Glioblastoma Xenografts with EGFR Amplification
Yoshida, Yasuyuki , Ozawa, Tomoko, Yao, Tsun-Wen, Wang, Shen , Brown, Dennis , Parsa, Andrew T., Raizer, Jeffrey J. , Cheng, Shi‐Yuan , Stegh, Alexander H. , Mazar, Andrew P. , Giles, Francis J., Butowski, Nicholas , Nicolaides, Theodore , James, C. David , Sarkaria, Jann N. , Cheng, Shi-Yuan , Nicolaides, Theodore

Mayo Clinic

Molecular Cancer Therapeutics | October 13, 2014 | Volume: 13 | Issue: 12 | Pages: 2919-2929

10.1158/1535-7163.mct-14-0306 | PMID 25313012 Get It

Abstract This report describes results from our analysis of the activity and biodistribution of a novel pan-ERBB inhibitor, NT113, when used in treating mice with intracranial glioblastoma (GBM) xenografts. Approaches used in this investigation include: bioluminescence imaging (BLI) for monitoring intracranial tumor growth and response to therapy; determination of survival benefit from treatment; analysis of tumor IHC reactivity for indication of treatment effect on proliferation and apoptotic response; Western blot analysis for determination of effects of treatment on ERBB and ERBB signaling mediator activation; and high-performance liquid chromatography for determination of NT113 concentration in tissue extracts from animals receiving oral administration of inhibitor. Our results show that NT113 is active against GBM xenografts in which wild-type EGFR or EGFRvIII is highly expressed. In experiments including lapatinib and/or erlotinib, NT113 treatment was associated with the most substantial improvement in survival, as well as the most substantial tumor growth inhibition, as indicated by BLI and IHC results. Western blot analysis results indicated that NT113 has inhibitory activity, both in vivo and in vitro, on ERBB family member phosphorylation, as well as on the phosphorylation of downstream signaling mediator Akt. Results from the analysis of animal tissues revealed significantly higher NT113 normal brain-to-plasma and intracranial tumor-to-plasma ratios for NT113, relative to erlotinib, indicating superior NT113 partitioning to intracranial tissue compartments. These data provide a strong rationale for the clinical investigation of NT113, a novel ERBB inhibitor, in treating patients with GBM. Mol Cancer Ther; 13(12); 2919–29. ©2014 AACR.
SCCA1/SERPINB3 Promotes Oncogenesis and Epithelial–Mesenchymal Transition via the Unfolded Protein Response and IL6 Signaling
Sheshadri, Namratha , Catanzaro, Joseph M., Bott, Alex J. , Ullman, Erica , Chen, Emily I., Pan, Ji-An , Zhang, Jianhua , Zong, Wei‐Xing , Crawford, Howard C, Sun, Yu , Wu, Song , Crawford, Howard C.

Mayo Clinic

Cancer Research | September 11, 2014 | Volume: 74 | Issue: 21 | Pages: 6318-6329

10.1158/0008-5472.can-14-0798 | PMID 25213322 Get It

Abstract The serine/cysteine protease inhibitor SCCA1 (SERPINB3) is upregulated in many advanced cancers with poor prognosis, but there is limited information about whether it makes functional contributions to malignancy. Here, we show that SCCA1 expression promoted oncogenic transformation and epithelial–mesenchymal transition (EMT) in mammary epithelial cells, and that SCCA1 silencing in breast cancer cells halted their proliferation. SCCA1 overexpression in neu+ mammary tumors increased the unfolded protein response (UPR), IL6 expression, and inflammatory phenotypes. Mechanistically, SCCA1 induced a prolonged nonlethal increase in the UPR that was sufficient to activate NF-κB and expression of the protumorigenic cytokine IL6. Overall, our findings established that SCCA1 contributes to tumorigenesis by promoting EMT and a UPR-dependent induction of NF-κB and IL6 autocrine signaling that promotes a protumorigenic inflammation. Cancer Res; 74(21); 6318–29. ©2014 AACR.
Chronic passive venous congestion drives hepatic fibrogenesis via sinusoidal thrombosis and mechanical forces
Simonetto, Douglas A. , Yang, Hui‐yin, Yin, Meng , Assuncao, Thiago M. de , Kwon, Jung Hee, Hilscher, Moira , Pan, Shuchong, Yang, Liu , Bi, Yan , Cao, Sheng , Simari, Robert D., Kamath, Patrick S. , Shah, Vijay H. , Yang, Hui-yin, Beyder, Arthur , Ehman, Richard L. , Yin, Meng , Simonetto, Douglas A , Yang, Liu

Mayo Clinic

Hepatology | August 20, 2014 | Volume: 61 | Issue: 2 | Pages: 648-659

10.1002/hep.27387 | PMID 25142214 Get It

Chronic passive hepatic congestion (congestive hepatopathy) leads to hepatic fibrosis; however, the mechanisms involved in this process are not well understood. We developed a murine experimental model of congestive hepatopathy through partial ligation of the inferior vena cava (pIVCL). C57BL/6 and transgenic mice overexpressing tissue factor pathway inhibitor (SM22α‐TFPI) were subjected to pIVCL or sham. Liver and blood samples were collected and analyzed in immunohistochemical, morphometric, real‐time polymerase chain reaction, and western blot assays. Hepatic fibrosis and portal pressure were significantly increased after pIVCL concurrent with hepatic stellate cell (HSC) activation. Liver stiffness, as assessed by magnetic resonance elastography, correlated with portal pressure and preceded fibrosis in our model. Hepatic sinusoidal thrombosis as evidenced by fibrin deposition was demonstrated both in mice after pIVCL as well as in humans with congestive hepatopathy. Warfarin treatment and TFPI overexpression both had a protective effect on fibrosis development and HSC activation after pIVCL. In vitro studies show that congestion stimulates HSC fibronectin (FN) fibril assembly through direct effects of thrombi as well as by virtue of mechanical strain. Pretreatment with either Mab13 or Cytochalasin‐D, to inhibit β‐integrin or actin polymerization, respectively, significantly reduced fibrin and stretch‐induced FN fibril assembly. Conclusion : Chronic hepatic congestion leads to sinusoidal thrombosis and strain, which in turn promote hepatic fibrosis. These studies mechanistically link congestive hepatopathy to hepatic fibrosis. (H epatology 2015;61:648‐659)
Characterization of a Resident Population of Adventitial Macrophage Progenitor Cells in Postnatal Vasculature
Psaltis, Peter J. , Puranik, Amrutesh S. , Spoon, Daniel B., Chue, Colin D. , Hoffman, Scott J., Witt, Tyra A. , Delacroix, Sinny , Kleppe, Laurel S., Mueske, Cheryl S., Pan, Shuchong, Gulati, Rajiv , Simari, Robert D., Puranik, Amrutesh S

Mayo Clinic

Circulation Research | June 7, 2014 | Volume: 115 | Issue: 3 | Pages: 364-375

10.1161/circresaha.115.303299 | PMID 24906644 Get It

Rationale : Macrophages regulate blood vessel structure and function in health and disease. The origins of tissue macrophages are diverse, with evidence for local production and circulatory renewal. Objective : We identified a vascular adventitial population containing macrophage progenitor cells and investigated their origins and fate. Methods and Results : Single-cell disaggregates from adult C57BL/6 mice were prepared from different tissues and tested for their capacity to form hematopoietic colony-forming units. Aorta showed a unique predilection for generating macrophage colony-forming units. Aortic macrophage colony-forming unit progenitors coexpressed stem cell antigen-1 and CD45 and were adventitially located, where they were the predominant source of proliferating cells in the aortic wall. Aortic Sca-1 + CD45 + cells were transcriptionally and phenotypically distinct from neighboring cells lacking stem cell antigen-1 or CD45 and contained a proliferative (Ki67 + ) Lin − c-Kit + CD135 − CD115 + CX 3 CR1 + Ly6C + CD11b − subpopulation, consistent with the immunophenotypic profile of macrophage progenitors. Adoptive transfer studies revealed that Sca-1 + CD45 + adventitial macrophage progenitor cells were not replenished via the circulation from bone marrow or spleen, nor was their prevalence diminished by depletion of monocytes or macrophages by liposomal clodronate treatment or genetic deficiency of macrophage colony-stimulating factor. Rather adventitial macrophage progenitor cells were upregulated in hyperlipidemic ApoE −/− and LDL-R −/− mice, with adventitial transfer experiments demonstrating their durable contribution to macrophage progeny particularly in the adventitia, and to a lesser extent the atheroma, of atherosclerotic carotid arteries. Conclusions : The discovery and characterization of resident vascular adventitial macrophage progenitor cells provides new insight into adventitial biology and its participation in atherosclerosis and provokes consideration of the broader existence of local macrophage progenitors in other tissues.
The pan‐caspase inhibitor Emricasan (IDN‐6556) decreases liver injury and fibrosis in a murine model of non‐alcoholic steatohepatitis
Barreyro, Fernando Javier , Holod, Silvia, Finocchietto, Paola, Camino, Alejandra, Aquino, Jorge B. , Avagnina, Alejandra , Carreras, Marı́a C., Poderoso, Juan J., Gores, Gregory J.

Mayo Clinic

Liver International | April 22, 2014 | Volume: 35 | Issue: 3 | Pages: 953-966

10.1111/liv.12570 | PMID 24750664 Get It

AbstractBackground & AimsHepatocyte apoptosis, the hallmark of non‐alcoholic steatohepatitis (NASH) contributes to liver injury and fibrosis. Although, both the intrinsic and extrinsic apoptotic pathways are involved in the pathogenesis ofNASH, the final common step of apoptosis is executed by a family of cysteine‐proteases termed caspases. Thus, our aim was to ascertain if administration of Emricasan, a pan‐caspase inhibitor, ameliorates liver injury and fibrosis in a murine model ofNASH.MethodsC57/BL6J‐mice were fed regular chow or high fat diet (HFD) for 20 weeks. All mice were treated with vehicle or Emricasan.ResultsMice fed a HFD diet demonstrate a five‐fold increase in hepatocyte apoptosis by the TUNEL assay and a 1.5‐fold and 1.3‐fold increase in caspase‐3 and‐8 activities respectively; this increase in apoptosis was substantially attenuated in mice fed a HFD treated with Emricasan (HFD‐Em). Likewise, liver injury and inflammation were reduced in mice fed HFD‐Em as compare to HFD by measuring serum aspartate aminotransferase and alanine aminotransferase levels, NAS histological score and IL 1‐β, TNF‐α, monocyte chemoattractant protein (MCP‐1) and C‐X‐C chemokine ligand‐2 (CXCL2) quantitative reverse‐transcription polymerase chain reaction (qPCR). These differences could not be attributed to differences in hepatic steatosis as liver triglycerides content were similar in both HFD groups. Hepatic fibrosis was reduced by Emricasan in HFD animals by decreasing αSMA (a marker for hepatic stellate cell activation), fibrosis score, Sirius red staining, hydroxyproline liver content and profibrogenic cytokines by qPCR.ConclusionIn conclusion, these data demonstrate that in a murine model ofNASH, liver injury and fibrosis are suppressed by inhibiting hepatocytes apoptosis and suggests that Emricasan may be an attractive antifibrotic therapy inNASH.
HLA-DRB1*0402 (DW10) Transgene Protects Collagen- Induced Arthritis-Susceptible H2Aq and DRB1*0401 (DW4) Transgenic Mice from Arthritis
Taneja, Veena , Behrens, Marshall D., Pan, Suchong, Trejo, Tad, Luthra, Harvinder S., David, Chella S., Taneja, Neelam , Trejo, Tad, Griffiths, Marie , Taneja, Veena

Mayo Clinic

The Journal of Immunology | April 21, 2014 | Volume: 171 | Issue: 8 | Pages: 4431-4438

10.4049/jimmunol.171.8.4431 | PMID 14530370 Get It

Abstract To investigate the role of HLA-DR4 in predisposition to arthritis, we generated transgenic mice carrying DRB1*0401 and DRB1*0402 genes. We have previously shown that DRB1*0401 molecule renders B10.RQB3 (H2Aq) mice susceptible to porcine and human type II collagen-induced arthritis. We report that the introduction of DRB1*0402 transgene does not lead to development of arthritis in mice when they are immunized with porcine and human type II collagen. In addition, DRB1*0402 protects B10.RQB3 mice against developing arthritis with bovine type II collagen. These data show that DRB1 can modulate the disease mediated by Aq. In vivo depletion of DRB1*0402 did not lead to induction of collagen-induced arthritis in transgenic mice. In vitro cytokine analysis shows that mice protected from collagen-induced arthritis produce lower amounts of Th1 and higher levels of Th2 type cytokines upon immunization with type II collagen. Protection of mice was also related to higher apoptosis in DW10 mice as indicated by higher amounts of BclII in response to type II collagen. On the basis of our observations in HLA transgenic mice, we hypothesize that DRB1 polymorphism can modulate disease by shaping the T cell repertoire in thymus and select autoreactive T cells.
CBP Loss Cooperates with PTEN Haploinsufficiency to Drive Prostate Cancer: Implications for Epigenetic Therapy
Ding, Liya , Pan, Yunqian , Zhong, Jian , Regan, Kevin M., Wang, Liguo , Yu, Chunrong, Rizzardi, Anthony E., Zhang, Jun , Schmechel, Stephen C. , Cheville, John C. , Deursen, Jan van, Tindall, Donald J., Cheng, Liang , Chen, Daiwen , Liu, Ping , Cheng, Liang , Huang, Haojie , Wang, Liguo , Cheng, Liang

Mayo Clinic

Cancer Research | February 3, 2014 | Volume: 74 | Issue: 7 | Pages: 2050-2061

10.1158/0008-5472.can-13-1659 | PMID 24491799 Get It

Abstract Despite the high incidence and mortality of prostate cancer, the etiology of this disease is not fully understood. In this study, we develop functional evidence for CBP and PTEN interaction in prostate cancer based on findings of their correlate expression in the human disease. Cbppc−/−;Ptenpc+/− mice exhibited higher cell proliferation in the prostate and an early onset of high-grade prostatic intraepithelial neoplasia. Levels of EZH2 methyltransferase were increased along with its Thr350 phosphorylation in both mouse Cbp−/−; Pten+/− and human prostate cancer cells. CBP loss and PTEN deficiency cooperated to trigger a switch from K27-acetylated histone H3 to K27-trimethylated bulk histones in a manner associated with decreased expression of the growth inhibitory EZH2 target genes DAB2IP, p27KIP1, and p21CIP1. Conversely, treatment with the histone deacetylase inhibitor panobinostat reversed this switch, in a manner associated with tumor suppression in Cbppc−/−;Ptenpc+/− mice. Our findings show how CBP and PTEN interact to mediate tumor suppression in the prostate, establishing a central role for histone modification in the etiology of prostate cancer and providing a rationale for clinical evaluation of epigenetic-targeted therapy in patients with prostate cancer. Cancer Res; 74(7); 2050–61. ©2014 AACR.
p300 Acetyltransferase Regulates Androgen Receptor Degradation and PTEN-Deficient Prostate Tumorigenesis
Zhong, Jian , Ding, Liya , Bohrer, Laura R., Pan, Yunqian , Liu, Ping , Sebo, Thomas J., Karnes, R. Jeffrey , Tindall, Donald J., Deursen, Jan van, van Deursen, Jan, Zhang, Jun , Huang, Haojie

Mayo Clinic

Cancer Research | January 30, 2014 | Volume: 74 | Issue: 6 | Pages: 1870-1880

10.1158/0008-5472.can-13-2485 | PMID 24480624 Get It

Abstract Overexpression of the histone acetyltransferase p300 is implicated in the proliferation and progression of prostate cancer, but evidence of a causal role is lacking. In this study, we provide genetic evidence that this generic transcriptional coactivator functions as a positive modifier of prostate tumorigenesis. In a mouse model of PTEN deletion–induced prostate cancer, genetic ablation of p300 attenuated expression of the androgen receptor (AR). This finding was confirmed in human prostate cancer cells in which PTEN expression was abolished by RNA interference–mediated attenuation. These results were consistent with clinical evidence that the expression of p300 and AR correlates positively in human prostate cancer specimens. Mechanistically, PTEN inactivation increased AR phosphorylation at serine 81 (Ser81) to promote p300 binding and acetylation of AR, thereby precluding its polyubiquitination and degradation. In support of these findings, in PTEN-deficient prostate cancer in the mouse, we found that p300 was crucial for AR target gene expression. Taken together, our work identifies p300 as a molecular determinant of AR degradation and highlights p300 as a candidate target to manage prostate cancer, especially in cases marked by PTEN loss. Cancer Res; 74(6); 1870–80. ©2014 AACR.